Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Cereno Scientific B

Cereno Scientific B

Cereno Scientific B

2026 Q1 -tulosraportti

Vain PDF

20 päivää sitten

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
600--
5 483--
1 424--
17 108--
4 511--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
26.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
27.5.
2025 Q4 -tulosraportti
27.2.
2025 Q3 -tulosraportti
27.11.2025
2025 Q2 -tulosraportti
27.8.2025
2025 Q1 -tulosraportti
22.5.2025

Foorumi

Liity keskusteluun Nordnet Socialissa
  • 1 päivä sitten · Muokattu
    ·
    1 päivä sitten · Muokattu
    ·
    Seriously, I said it on the way up a few days ago too... Can we try to have a sensible debate here instead of throwing insults and making nasty comments to each other? This applies to both those of us who think the price should be higher and those who think it should be lower. I asked a few days ago and I'm asking again. Can we agree that rNPV is a sensible model for clarifying what the company should be worth? If not, what alternative model do you suggest? If we agree on that, what assumptions do you think one should / should not take into account? As I wrote below, I have made a proposal for an rNPV calculator that is based on Edison's valuation. (disclaimer, I don't know their model and have used AI to create my model, it's probably not 100%, but let's discuss it so it gets better) Link to the calculator is here: https://claude.ai/public/artifacts/cdcb9883-3342-4f6e-a1e5-51f3ef25fd1a If we can discuss the different variables in such a valuation together, we should be able to get closer to an understanding of what we think the company should be worth and why we might disagree with the valuation. I believe it will give us all greater understanding, and better patience with others' viewpoints. Those who talk the price up or down without contributing to this can go take a hike for all I care. Then you are here to pump or dump and your opinion means absolutely nothing to me. Looking forward to responses, let the debate begin!
    6 t sitten
    6 t sitten
    Your rNPV model looks good, as far as I understand the model‘s general basis. Kudos for doing something productive for not only yourself, but the community as a whole. I cannot think of a better alternative for a model to use than rNPV, so by a process of elimination and a lack of a better substitute - I‘ll agree with your choice of model. What I don‘t necessarily agree with are the estimated values for the model that come from Edison. Peak sales numbers are (correct me if I‘m wrong) guesstimations based off of Sotatercept sales and the total value of the PAH market? While it‘s probably the best we can do for now, my personal standing would be on a lower basis for those numbers - but that‘s just my pessimistic side. What I’m really interested in is which - if any - of the variables in the calculator model the cash burn rate and dillutive effects of further rounds of financing? I saw variables labeled R&D cost (or something of the kind) but I‘d love to know more in detail how they affect the pricing function of the model and whether they actively take into account the dilutive effect of funding.
    2 t sitten
    ·
    2 t sitten
    ·
    Thanks for the feedback! Busy with football, but will look at it tomorrow. Go Norway!
  • 1 päivä sitten
    1 päivä sitten
    So, how is the price development holding up guys?
    12 t sitten
    ·
    12 t sitten
    ·
    Shape up, folks... We should be better than this....
  • 12.6.
    ·
    12.6.
    ·
    the skeptics are quiet, I thought the price would hit 1 before it came up again ?
    12.6.
    ·
    12.6.
    ·
    @GrazieMille99 Do you know that CU data, fluidda readout shall be reported as well as FPI in phase 2B for CS1. In case of a positive outcome, it is likely to bounce up quite well. I don't think the company will have difficulty raising money regardless.
  • 11.6.
    ·
    11.6.
    ·
    Anyone know anything, maybe?
    11.6. · Muokattu
    ·
    11.6. · Muokattu
    ·
    Perhaps Alzecure also saw that a deal is possible in 2026 or 2027 :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q1 -tulosraportti

Vain PDF

20 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
  • 1 päivä sitten · Muokattu
    ·
    1 päivä sitten · Muokattu
    ·
    Seriously, I said it on the way up a few days ago too... Can we try to have a sensible debate here instead of throwing insults and making nasty comments to each other? This applies to both those of us who think the price should be higher and those who think it should be lower. I asked a few days ago and I'm asking again. Can we agree that rNPV is a sensible model for clarifying what the company should be worth? If not, what alternative model do you suggest? If we agree on that, what assumptions do you think one should / should not take into account? As I wrote below, I have made a proposal for an rNPV calculator that is based on Edison's valuation. (disclaimer, I don't know their model and have used AI to create my model, it's probably not 100%, but let's discuss it so it gets better) Link to the calculator is here: https://claude.ai/public/artifacts/cdcb9883-3342-4f6e-a1e5-51f3ef25fd1a If we can discuss the different variables in such a valuation together, we should be able to get closer to an understanding of what we think the company should be worth and why we might disagree with the valuation. I believe it will give us all greater understanding, and better patience with others' viewpoints. Those who talk the price up or down without contributing to this can go take a hike for all I care. Then you are here to pump or dump and your opinion means absolutely nothing to me. Looking forward to responses, let the debate begin!
    6 t sitten
    6 t sitten
    Your rNPV model looks good, as far as I understand the model‘s general basis. Kudos for doing something productive for not only yourself, but the community as a whole. I cannot think of a better alternative for a model to use than rNPV, so by a process of elimination and a lack of a better substitute - I‘ll agree with your choice of model. What I don‘t necessarily agree with are the estimated values for the model that come from Edison. Peak sales numbers are (correct me if I‘m wrong) guesstimations based off of Sotatercept sales and the total value of the PAH market? While it‘s probably the best we can do for now, my personal standing would be on a lower basis for those numbers - but that‘s just my pessimistic side. What I’m really interested in is which - if any - of the variables in the calculator model the cash burn rate and dillutive effects of further rounds of financing? I saw variables labeled R&D cost (or something of the kind) but I‘d love to know more in detail how they affect the pricing function of the model and whether they actively take into account the dilutive effect of funding.
    2 t sitten
    ·
    2 t sitten
    ·
    Thanks for the feedback! Busy with football, but will look at it tomorrow. Go Norway!
  • 1 päivä sitten
    1 päivä sitten
    So, how is the price development holding up guys?
    12 t sitten
    ·
    12 t sitten
    ·
    Shape up, folks... We should be better than this....
  • 12.6.
    ·
    12.6.
    ·
    the skeptics are quiet, I thought the price would hit 1 before it came up again ?
    12.6.
    ·
    12.6.
    ·
    @GrazieMille99 Do you know that CU data, fluidda readout shall be reported as well as FPI in phase 2B for CS1. In case of a positive outcome, it is likely to bounce up quite well. I don't think the company will have difficulty raising money regardless.
  • 11.6.
    ·
    11.6.
    ·
    Anyone know anything, maybe?
    11.6. · Muokattu
    ·
    11.6. · Muokattu
    ·
    Perhaps Alzecure also saw that a deal is possible in 2026 or 2027 :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
600--
5 483--
1 424--
17 108--
4 511--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
26.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
27.5.
2025 Q4 -tulosraportti
27.2.
2025 Q3 -tulosraportti
27.11.2025
2025 Q2 -tulosraportti
27.8.2025
2025 Q1 -tulosraportti
22.5.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q1 -tulosraportti

Vain PDF

20 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
26.8.
Menneet tapahtumat
2026 Q1 -tulosraportti
27.5.
2025 Q4 -tulosraportti
27.2.
2025 Q3 -tulosraportti
27.11.2025
2025 Q2 -tulosraportti
27.8.2025
2025 Q1 -tulosraportti
22.5.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
  • 1 päivä sitten · Muokattu
    ·
    1 päivä sitten · Muokattu
    ·
    Seriously, I said it on the way up a few days ago too... Can we try to have a sensible debate here instead of throwing insults and making nasty comments to each other? This applies to both those of us who think the price should be higher and those who think it should be lower. I asked a few days ago and I'm asking again. Can we agree that rNPV is a sensible model for clarifying what the company should be worth? If not, what alternative model do you suggest? If we agree on that, what assumptions do you think one should / should not take into account? As I wrote below, I have made a proposal for an rNPV calculator that is based on Edison's valuation. (disclaimer, I don't know their model and have used AI to create my model, it's probably not 100%, but let's discuss it so it gets better) Link to the calculator is here: https://claude.ai/public/artifacts/cdcb9883-3342-4f6e-a1e5-51f3ef25fd1a If we can discuss the different variables in such a valuation together, we should be able to get closer to an understanding of what we think the company should be worth and why we might disagree with the valuation. I believe it will give us all greater understanding, and better patience with others' viewpoints. Those who talk the price up or down without contributing to this can go take a hike for all I care. Then you are here to pump or dump and your opinion means absolutely nothing to me. Looking forward to responses, let the debate begin!
    6 t sitten
    6 t sitten
    Your rNPV model looks good, as far as I understand the model‘s general basis. Kudos for doing something productive for not only yourself, but the community as a whole. I cannot think of a better alternative for a model to use than rNPV, so by a process of elimination and a lack of a better substitute - I‘ll agree with your choice of model. What I don‘t necessarily agree with are the estimated values for the model that come from Edison. Peak sales numbers are (correct me if I‘m wrong) guesstimations based off of Sotatercept sales and the total value of the PAH market? While it‘s probably the best we can do for now, my personal standing would be on a lower basis for those numbers - but that‘s just my pessimistic side. What I’m really interested in is which - if any - of the variables in the calculator model the cash burn rate and dillutive effects of further rounds of financing? I saw variables labeled R&D cost (or something of the kind) but I‘d love to know more in detail how they affect the pricing function of the model and whether they actively take into account the dilutive effect of funding.
    2 t sitten
    ·
    2 t sitten
    ·
    Thanks for the feedback! Busy with football, but will look at it tomorrow. Go Norway!
  • 1 päivä sitten
    1 päivä sitten
    So, how is the price development holding up guys?
    12 t sitten
    ·
    12 t sitten
    ·
    Shape up, folks... We should be better than this....
  • 12.6.
    ·
    12.6.
    ·
    the skeptics are quiet, I thought the price would hit 1 before it came up again ?
    12.6.
    ·
    12.6.
    ·
    @GrazieMille99 Do you know that CU data, fluidda readout shall be reported as well as FPI in phase 2B for CS1. In case of a positive outcome, it is likely to bounce up quite well. I don't think the company will have difficulty raising money regardless.
  • 11.6.
    ·
    11.6.
    ·
    Anyone know anything, maybe?
    11.6. · Muokattu
    ·
    11.6. · Muokattu
    ·
    Perhaps Alzecure also saw that a deal is possible in 2026 or 2027 :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
600--
5 483--
1 424--
17 108--
4 511--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt